Cetuximab, an anti-EGFR monoclonal antibody, has been approved for the treatment of colorectal cancer, as well as squamous cell carcinoma of the head and neck, and is in trials for the treatment of advanced pancreatic cancer [61]. The gene discussed is EGFR; the disease is pancreatic neoplasm.